Date: 2011-08-22
Type of information: Licensing agreement
Compound: Isconova’s adjuvant Matrix M™
Company: Isconova (Sweden) Genocea (USA)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: malaria gonorrhoea
Details: Isconova and Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, have announced the expansion of their collaboration granting Genocea the right to use Isconova’s Matrix M™ in vaccines targeting two additional diseases. The new disease targets included in the global collaboration are malaria and gonorrhoea. Genocea currently has the right to use Matrix M™ in vaccines targeting six infectious diseases including programs in its pipeline for herpes simplex virus type-2, Chlamydia trachomatis, and Streptococcus pneumoniae. The lead program of the collaboration is a therapeutic vaccine for herpes simplex virus type-2. HSV-2 is a sexually transmitted disease that is estimated to infect more than 500 million people worldwide. Genocea expects to initiate human trials with this program in 2012.
Financial terms:
Latest news:
